Advertisement
U.S. Markets closed

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
0.01000.0000 (0.00%)
At close: 10:34AM EDT

Aequus Pharmaceuticals Inc.

200 Granville Street
Suite 2820
Vancouver, BC V6C 1S4
Canada
604 336 7906
https://www.aequuspharma.ca

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas Glen JanzenChairman, CEO & PresidentN/AN/A1969
Ms. Ann Fehr CGA, CPACFO & Corporate Secretary104.95kN/A1969
Mr. Grant LarsenChief Commercial Officer250kN/AN/A
Mr. Rabin RamanjooloChief Operating OfficerN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Corporate Governance

Aequus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.